BRAF and colorectal cancer: Their many therapeutic applications as single agents or in combination with MEK inhibitors (cobimetinib, binimetinib, and trametinib) and/or other agents including BRAF p.V600E-driven colorectal cancer, Erdheim-Chester disease, hematological malignancies, melanoma, non-small-cell lung cancer, and PTC [29,48,49,50,51,52].